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COST-EFFECTIVENESS ANALYSIS OF SINGLE-DOSE
EXTENDED RELEASE METHYLPHENIDATE (CONCERTA®) VS.
ATOMOXETINE AND SHORT-ACTION METHYLPHENIDATE,
FOR THE MANAGEMENT OF ATTENTION DEFICIT DISORDER
WITH HYPERACTIVITY IN MEXICO
Vazquez V
Janssen-Cilag, Mexico, Mexico
OBJECTIVES: To estimate the cost-effectiveness of the single-
dose extended release Methylphenidate vs the multi-dose imme-
diate release Methylphenidate and single-dose Atomoxetine 
for the management of ADDH in Mexico. METHODS: A cost-
effectiveness analysis was developed, under a decision model.
The cost-effectiveness ratio was estimated for extended release
methylphenidate compared to other drug alternatives. A retro-
spective analysis was made of all patients seen at the IMSS
(Mexican Institute of Social Security) during 2004, with diag-
nosed ADDH. Patient cohorts were derived from IMSS data
base, and they were used as an analysis pattern for each thera-
peutic alternative. In order to determine the effectiveness rates
for each drug, and to obtain the “clinical outcomes”, a meta-
analysis of national and international literature was made. To
compare the effectiveness, the ADHR-RS/Total, ADHD-RS/
Hyperactivity, ADHD-RS/Attention, CPRS-R Inattention/Over-
activity and CPRS-R/Opposition-Challenge scales were used. A
comparison was also made of all reported adverse events. A 
decision tree was utilized, based on its care, and the costs were
determined for each node. Costs for drug therapy, specialty
ambulatory consultations in pediatrics, neurology, and psychol-
ogy, hospitalization, time spent in hospitals, laboratory and
ofﬁce tests, and labor productivity were considered. RESULTS:
The extended release methylphenidate OROS attained the most
signiﬁcant results regarding health care measures. As for the
ADHD-RS Total score, it showed a difference in improvement
of almost 34%, compared to Methylphenidate IR, and almost
59% compared to Atomoxetine. The extended release
methylphenidate OROS (CONCERTA®) leads to savings of
$3213 for hospitalization days avoided, and it is the most cost-
effective and cost-saving strategy, compared to Methylphenidate
IR and Atomoxetine. CONCLUSION: Extended release
methylphenidate OROS is an efﬁcient, cost-effective, and 
cost-saving alternative compared to Methylphenidate IR and 
Atomoxetine.
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COST-EFFECTIVENESS ANALYSIS OF GALANTAMINE
(REMINYL ER) IN THE TREATMENT OF MILD TO MODERATE
DEMENTIA OF THE ALZHEMIER’S TYPE IN MEXICO
Agramonte J
Janssen-Cilag,SA de CV, Mexico City, Mexico
OBJECTIVES: To estimate the cost-effectiveness of Galantamine
in the extended release formulation for the management of
Alzheimer’s Disease (AD) versus other acetylcholinesterase
inhibitors (Donepezil, Rivastigmine and Galantamine immediate
release formulation) in Mexico. METHODS: A decision analy-
sis was developed using a cost-effectiveness study, based on a
Markov model, in order to understand the different stages of the
disease over a period of 48 months. The databases of the
Mexican Social Security Institute (IMSS) were consulted in a ret-
rospective manner and a cohort of patients was used to deter-
mine the consumption of resources. The factors taken into
consideration were: speciﬁc pharmacological therapy, outpatient
consultation in family practice and specialty units, hospital stays,
number of days hospitalized, emergency care and laboratory
tests. To determine the effectiveness of each of the medications,
a meta-analysis was carried out to compare clinical outcomes
according to the ADAS-cog and CIBIC-plus scales. The different
parameters of effectiveness were included in the model and con-
sumption of resources also, with each therapeutic formulation.
RESULTS: Galantamine ER was the alternative with the lowest
annual cost of treatment, both in the highest recommended dose
range ($43,162 pesos) as well as the lowest dose range ($28,214
pesos). Galantamine ER produced savings of $18,314 pesos in
the highest dose range and $6789 pesos in the lowest dose range
versus Donepezil. Galantamine ER produced savings of $76,230
pesos and $20,274 pesos (highest and lowest recommended dose
ranges, respectively) versus Rivastigmine; and $23,033 pesos and
$18,559 pesos versus Galantamine IR. Galantamine ER revealed
the lowest number of days hospitalized/year, a situation that is
extremely relevant for the National Health care Institute. CON-
CLUSION: Galantamine ER is a dominant cost-efﬁcient and
cost-saving alternative for the management of Alzheimer patients
in Mexico.
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